Anastrozole-related acute hepatitis with autoimmune features: a case report by Inno, Alessandro et al.
CASE REPORT Open Access
Anastrozole-related acute hepatitis with
autoimmune features: a case report
Alessandro Inno
1, Michele Basso
1, Fabio M Vecchio
2, Valentina A Marsico
1, Eleonora Cerchiaro
1, Ettore D’Argento
1,
Cinzia Bagalà
1 and Carlo Barone
1*
Abstract
Background: Two cases of acute hepatitis occurring during treatment with anastrozole have previously been
reported, but the underlying mechanisms of liver injury are still uncertain. We report the case of anastrozole-related
acute hepatitis with some autoimmune features.
Case presentation: A 70-year-old woman developed acute hepatitis associated with serum antinuclear antibodies
during anastrozole treatment; after drug withdrawal, liver function parameters rapidly improved and serum auto-
antibodies were no longer detectable.
Conclusions: Anastrozole-induced hepatotoxicity is a very rare event. Drug-drug interactions or metabolically-
mediated damage might be involved, with a possible role of individual susceptibility. Our report suggests that an
immune-mediated mechanism may also be considered in anastrozole-related liver injury.
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Background
Anastrozole is a selective aromatase inhibitor approved
for the treatment of postmenopausal hormone-sensitive
breast cancer [1]. The principal side effects are osteo-
porosis resulting in increased incidence of bone frac-
tures, hypercholesterolemia with no significant increase
in cardiovascular risk, and musculoskeletal events such
as arthralgia and myalgia [2].
Other adverse events have been less frequently reported,
including two cases of severe acute hepatitis [3,4]; how-
ever, the underlying mechanisms of anastrozole-related
liver injury are still poorly understood. We report a case of
anastrozole-related acute hepatitis associated with serum
antinuclear antibodies, suggesting a possible role of the
immune system in anastrozole-related liver damage.
Case presentation
A 70-year-old woman underwent left upper-lateral quad-
rantectomy and axillary dissection for a high grade 2,5 cm
intra-ductal breast carcinoma in June, 2008. Tumor cells
were ER positive and PR negative, immunohistochemistry
staining for c-ErbB2 was negative, Ki67 was 35%; no
metastases were found in 21 axillary lymph nodes. Chest
radiography, abdominal ultrasound and bone scintigraphy
showed no distant metastases. Anti-estrogen treatment
with anastrozole (1 mg/day) was started in August 2008,
and whole breast radiotherapy (5000 cGy) was delivered
from November to December 2008, followed by a boost to
the tumor bed (1000 cGy). The only concomitant com-
plaint was arterial hypertension, which had been treated
with ramipril, bisoprolol and manidipine for about three
years prior to the onset of breast cancer. Before starting
anastrozole, liver function tests were normal: aspartate
aminotransferase 18 U/l (normal range: 7-45), alanine ami-
notransferase 25 UI/l (normal range: 7-45), alkaline phos-
phatase 158 U/l (normal range: 98-279), total bilirubin 1.2
mg/dl (normal range:0.3-1.2) and gamma-glutamyltrans-
ferase 10 (normal range 5-36).
In January 2009, i.e. four months after beginning
anastrozole, the patient developed mild asthenia.
Laboratory tests showed changes consistent with a
mixed hepatocellular and cholestatic liver injury:
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ferase 1344 U/l, alkaline phosphatase 355 U/l, total bilir-
ubin 3.54 mg/dl, conjugated bilirubin 2.29 mg/dl,
gamma glutamyltransferase 234 U/l. Anastrozole was
withdrawn and the patient was hospitalized. Hepatitis A,
B and C and Epstein-Barr virus serology were negative;
IgM-type antibodies (Abs) against cytomegalovirus were
also absent. Anti-smooth muscle, anti-liver and kidney
microsomal, anti-neutrophil cytoplasmic, anti-mitochon-
dral, anti-native DNA, anti-extractable nuclear antigens
and anti-gastric parietal cell Abs were negative. Anti-
nuclear Abs, however, were positive with 1:80 titer and
a speckled pattern. Abdominal ultrasound and CT scan
showed no hepatic lesions, only a mild dilatation of the
intrahepatic biliary tract without biliary stones or evi-
dence of other possible causes of biliary duct obstruc-
tion. A liver biopsy was performed and histological
examination revealed a pattern of mild steatosis (10%),
with moderate inflammatory activity and moderate to
severe fibrosis, totalizing a 5-6 score according to Ishak’s
classification (Figure 1) [5].
After anastrozole discontinuation, a dramatic clinical
and laboratory improvement was observed. Mainly for
this reason other imaging procedures were considered
unncecessary. Liver parameters returned to normal
ranges in one month; subsequently, the anti-estrogen
schedule was switched to tamoxifen with no side effects.
Interestingly, twelve months later even serum anti-
nuclear Abs were undetectable.
Discussion
In clinical trials, anastrozole has generally shown a good
liver safety profile [6]. Our patient, however, developed
acute liver damage during treatment with this aromatase
inhibitor, but achieved a prompt and full recovery after
discontinuation of the drug. Overall, the time lapse
between drug exposure and the onset of hepatitis, the
age of the patient, the exclusion of other non-drug-
related causes, the improvement achieved after drug
withdrawal and other reported cases of anastrozole-
related hepatitis, allow our case to achieve a score of 7
according the Roussel-Uclaf Causality Method; this
result suggests a probable correlation between anastro-
zole and liver damage [7].
Only two other cases of hepatitis occurring during
treatment with anastrozole have previously been
reported. The two patients, aged 58 and 89 years, devel-
oped acute, mainly cholestatic liver damage during ana-
strozole therapy; in both patients liver function tests
improved after drug withdrawal [3,4]. After excluding
other etiologic factors, anastrozole was considered the
most probable cause of liver injury. However, in the
case reported by Zapata et al, liver biopsy was not per-
formed, preventing any reliable pathogenetic assumption
[3]. In the case reported by de la Cruz et al, liver biopsy
revealed diffuse liver cell necrosis in acinar zone 3, the
preferred location of most drug-metabolizing P450 iso-
enzymes, but no inflammatory changes [4]. The authors
considered these findings compatible with a metaboli-
cally-mediated hepatocellular liver injury. Indeed,
anastrozole is extensively metabolized in the liver by N-
dealkylation, hydroxylation and glucuronidation; thus, a
genetic polymorphism of any enzyme involved in drug
detoxification could cause an accumulation of the
parental drug or its metabolites, predisposing to anastro-
zole-induced liver toxicity. Moreover, a cytochrome-
mediated drug-drug interaction might modify plasma
anastrozole concentrations, increasing the risk of toxic
effects. However, both the potential and the mechanisms
of anastrozole hepatotoxicity remain uncertain.
In the two previously reported cases, autoantibodies
were not found, whereas in our patient serum antinuc-
lear Abs were detected when hepatitis was recognized.
Interestingly, Abs were cleared after anastrozole with-
drawal, suggesting a link between antinuclear Abs and
exposure to the drug. The absence of a baseline value
only minimally affects this conclusion, assuming that
the normal laboratory condition reached after anastro-
zole withdrawal would be similar to the normal baseline
condition.
A metabolic interaction of anastrozole with simulta-
neously administered bisoprolol and manidipine seems
unlikely in our patient. Bisoprolol is metabolized by
CYP3A4, and manidipine can inhibit CYP2C9, both
cytochromes being in turn down-regulated by anastra-
zole [8]. Although a cytochrome-mediated interaction
could not be excluded, there are no pharmacological
Figure 1 Photomicrographs of liver biopsy, with hematoxylin/
eosin (A, B, C) and reticulin stain (D), revealing a pattern of
mild steatosis, moderate inflammatory changes and moderate
to severe fibrosis (Ishak score = 5-6).
Inno et al. BMC Gastroenterology 2011, 11:32
http://www.biomedcentral.com/1471-230X/11/32
Page 2 of 4studies that show a significant risk of CYP-mediated
drug-to-drug interactions with anastrozole, nor do biso-
prolol or manidipine seem to have a significant potential
for liver injury [9,10].
In our patient, liver biopsy showed no histological fea-
tures typical of autoimmune hepatitis (such as bridging
necrosis, hepatic rosettes or clusters of plasma cells
extending from the portal tract into the parenchyma);
nor, however, did it exhibit a pattern specific to any
other pathogenesis. Unfortunately, a complete score
according to Hennes’ diagnostic criteria for autoimmune
hepatitis could not be calculated, as serum immunoglo-
bulin levels were not determined at the onset of hepati-
tis [11]. However, the temporal relationship with
anastrozole, the presence of antinuclear antibodies and
the absence of viral hepatitis or other hepatic diseases,
taken together, are suggestive of an autoimmune
mechanism in the pathogenesis of this drug-induced
hepatitis. The rapid improvement of liver function
together with the disappearance of antinuclear Abs after
withdrawal of the aromatase inhibitor suggests that ana-
strozole may have induced hepatitis with autoimmune
features rather than brought to light an underlying liver
disease. Even though a long-term follow-up was not
available for our patient, anastrozole-induced hepatitis
seems a reversible, positive-prognosis and self-recover-
ing toxic event. These characteristics are similar to
those of autoimmune hepatitis induced by nitrofuran-
toine or minocycline, the two drugs mainly involved in
immune-mediated liver injury [12].
Interestingly, the use of anastrozole is associated with
a higher incidence of arthralgias and inflammatory
arthropathies than either placebo or tamoxifen, and
Laroche et al found antinuclear antibodies (titer >
1:160) in nine of twenty-four women treated with
aromatase inhibitors who developed arthralgias [13].
Autoimmune diseases such as Sjogren’s syndrome,
Schonlein-Henoch purpura and Rheumatoid Arthritis
have also been reported in patients treated with anastro-
zole [14,15]. Taken together, these reports support the
hypothesis that anastrozole might affect immune regula-
tion, probably by reducing self-tolerance, but the
mechanism of this possible interference is unknown.
Conclusions
Anastrozole-related hepatotoxicity is a rare and perhaps
underestimated event whose pathogenesis is not clear;
several factors, including an immune-mediated mechan-
ism, could be involved. In the present case and in the
others so far reported, a complete recovery followed ana-
strozole withdrawal. However, when anastrozole-related
liver injury is suspected, an exhaustive study is necessary,
including liver biopsy and a careful immunologic
assessment in order better to understand the mechan-
isms of toxicity.
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